Incretin receptor agonists have revolutionized the treatment of obesity, achieving up to 15–
25% weight loss in many patients, ie, at a rate approaching that achieved with bariatric …

Abstract Purpose of Review Despite the great progress in obesity-tackling strategies, a
negative energy equilibrium between energy expenditure and energy intake remains the …

Since its discovery and over the past thirty years, extensive research has significantly
expanded our understanding of leptin and its diverse roles in human physiology …

Metabolic effects of glucagon-like peptide 1 (GLP-1) receptor agonists are confounded by
weight loss and not fully recapitulated by increasing endogenous GLP-1. We tested the …

Metabolic dysfunction-associated steatotic liver disease (MASLD), precipitated by
intrahepatic ectopic lipid accumulation is, globally, the most commonly observed chronic …

Background & aims The ingestion of macronutrients triggers the release of several incretin
peptides from the gastrointestinal system, which have both insulinotropic and satiety …

Background Medications targeting the leptin and Apolipoprotein CIII (APOC3) pathways are
currently under development for the treatment of hypertriglyceridaemia. Given that both …

This paper is the forty-sixth consecutive installment of the annual anthological review of
research concerning the endogenous opioid system, summarizing articles published during …

Introdução: A obesidade, um desafio global, muitas vezes demanda abordagens múltiplas,
além da mudança de estilo de vida, como a farmacoterapia. A associação entre bupropiona …

Background Bariatric surgery has long-term beneficial effects on body weight and metabolic
status, but there is an apparent lack of comprehensive cardiometabolic, renal, liver, and …